Frontiers in neurologyAug 28, 2026

Exendin-4 as a treatment for brain injury caused by inflammation in unborn babies

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 29, 2026

Abstract

Exendin-4 may offer a multi-target approach to treating Fetal Inflammatory Response Syndrome (FIRS), a major cause of neonatal brain injury.

Exendin-4 is associated with reducing neuroinflammation and protecting oligodendrocytes.
It may help stabilize the blood-brain barrier and reduce excitotoxicity.
Emerging mechanisms include the reprogramming of microglia metabolism and improved mitophagy.
Challenges in drug delivery and therapeutic timing are noted for clinical application.
A precision medicine framework for developing Exendin-4 in this context is proposed.

Simplified

Fetal Inflammatory Response Syndrome (FIRS) is a leading cause of neonatal brain injury for which no specific treatment currently exists. This review proposes that Exendin-4, a glucagon-like peptide-1 receptor agonist, is a promising "network therapy" due to its multi-target actions against the interconnected pathologies of FIRS. We synthesize evidence that Exendin-4 can concurrently mitigate neuroinflammation, protect oligodendrocytes, stabilize the blood-brain barrier, and attenuate excitotoxicity. Furthermore, we explore emerging mechanisms such as microglial metabolic reprogramming and enhanced mitophagy. Finally, we critically evaluate the translational pathway, highlighting challenges in drug delivery and the therapeutic window, and outline a precision medicine framework for its clinical development. This work positions Exendin-4 as a key candidate for overcoming the therapeutic gap in FIRS-associated neuroprotection.

Full Text

Full text is available at the source.

View Full Text ↗

Exendin-4 as a treatment for brain injury caused by inflammation in unborn babies

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief